Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm³.

ABSTRACT:

Background

Co-infection with Mycobacterium tuberculosis remains a leading cause of morbidity and mortality among HIV infected individuals especially in developing countries. Early initiation of cART in these patients when CD4+ T cell count is less than 200cells/mm³ has reduced disease progression and mortality. However for patients with higher CD4+ T cell counts greater than 350cells/mm³ evidence is conflicting. In this study we seek to evaluate the effectiveness of cART in reducing mortality among TB-HIV co-infected patients with CD4 + T cells above 350cells/mm³ at the time of TB diagnosis.

Method

In a retrospective cohort study we analyzed 337 HIV-TB co-infected patients with CD4+ T cells above 350cells/mm³ at baseline who were d

SUBMITTER: Mutembo S 

PROVIDER: S-EPMC5067898 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature